Le Lézard
Classified in: Health, Science and technology, Business
Subjects: STOCK/OTHER MARKET NEWS, ANNUAL MEETINGS

Trillium Announces Voting Results From the Annual and Special Meeting of Shareholders


TORONTO, July 02, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its Annual and Special Meeting of Shareholders held on June 27, 2019. The results of the director elections were as follows:

          
  Votes in Favor % Votes in Votes % Votes 
 Name  Favor Withheld Withheld 
 Mr. Luke Beshar5,579,317 85 977,217 15 
 Dr. Robert Kirkman5,614,544 85 941,990 15 
 Dr. Michael Moore5,586,552 85 969,982 15 
 Dr. Thomas Reynolds5,580,252 85 976,282 15 
 Dr. Robert Uger5,615,550 86 940,984 14 
 Dr. Calvin Stiller5,581,832 85 974,702 15 
 Dr. Helen Tayton-Martin5,687,094 87 869,440 13 
          

The shareholders of the Corporation also voted to reappoint Ernst & Young LLP, Chartered Professional Accountants, Licensed Public Accountants as auditors of the Corporation for the ensuing year. In addition, the shareholders approved the special resolutions to continue the Corporation as a British Columbia corporation to be governed by the provisions of the Business Corporations Act and the potential consolidation of the Corporation's issued and outstanding common shares.

About Trillium Therapeutics:

Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company's two clinical programs, TTI-621 and TTI-622, target CD47, a "do not eat" signal that cancer cells frequently use to evade the immune system. Trillium also has a preclinical STING program and a proprietary fluorine-based medicinal chemistry platform that is being used to develop novel compounds directed at undisclosed immuno-oncology targets.

For more information visit: www.trilliumtherapeutics.com 

Investor Relations:
James Parsons
Chief Financial Officer
Trillium Therapeutics Inc.
416-595-0627 x232
james@trilliumtherapeutics.com


These press releases may also interest you

at 07:05
Castle Biosciences, Inc. , a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of data supporting the ability of the DecisionDx®-Melanoma gene expression...

at 07:05
Merck , known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending approval of two regimens of...

at 07:03
Rutherford Health today announced that it has secured a £20million facility with Triple Point Investment Management, the specialist impact investment manager. The nature of the Impact-Linked Pricing structure means Rutherford can enjoy more...

at 07:00
Bristol-Myers Squibb Company ("Bristol-Myers Squibb") announced today the extension of the expiration date of the offers to exchange (the "Exchange Offers") notes (the "Celgene Notes") issued by Celgene Corporation ("Celgene") for up to...

at 07:00
DEKRA Organizational Safety and Reliability (OSR), a global leader in safety at work, has announced a permanent and ongoing collaboration with Behavioral Safety Now (BSN) for the 2020 Safety In Action Conference. The...

at 07:00
Cipher Pharmaceuticals Inc. ("Cipher" or "the Company") today announced it has received Health Canada approval, on October 10, 2019, for TRULANCE® (plecanatide), a Guanylate cyclase-C (GCC) agonist in the form of a once-daily tablet for the...



News published on 2 july 2019 at 07:05 and distributed by: